Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

  • Technology appraisal guidance
  • TA445
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee (section 6) considered evidence from a number of sources. See the committee papers for full details of the evidence.